CHRONIC LIVER DISEASES THERAPEUTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

The liver is the largest solid internal organ of the body and performs various roles that include the creation of bile for food digestion, converting food into energy, and maintaining an adequate level of the chemical in the body that stores nutrients for all cellular and biological activities. Therefore, improper functioning of the liver can cause many severe diseases, which include hepatitis A, B, C, primary cirrhosis, and tumors. Some of the paramount reasons for improper liver functioning are obesity, excessive alcohol consumption, and genetic disorder. The treatment options available to treat liver diseases include antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. Moreover,  chronic liver diseases include hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others.

Market Dynamics      

The increasing population of chronic liver diseases, rising research and development activities for the development of novel technology for the treatment of liver diseases, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global chronic liver diseases therapeutics market over the forecast period. For instance, in December 2022, Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver disease, announced positive topline results from its 24-week (12-week extension) trial of Pemvidutide for non-alcoholic fatty liver disease, showing the potential to dramatically lower liver fat content and liver inflammation. Moreover, in January 2022, Madrigal Pharmaceuticals, Inc. l is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Our most advanced clinical candidate, resmetirom, announced positive topline clinical data from the placebo-controlled, double-blind version of its phase 3 MAESTRO-NAFLD (Non-Alcoholic Fatty Liver Disease) safety study of Resmetirom.

Key features of the study:

• This report provides an in-depth analysis of the global chronic liver diseases therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global chronic liver diseases therapeutics market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
• Global chronic liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Chronic Liver Diseases Therapeutics market.

Detailed Segmentation:

• Global Chronic Liver Diseases Therapeutics Market, By Treatment Type:
  • Antiviral drugs
  • Immunosuppressants
  • Vaccines
  • Immunoglobulins
  • Corticosteroids
  • Targeted Therapy
  • Chemotherapy
• Global Chronic Liver Diseases Therapeutics Market, By Disease Type:
  • Hepatitis
  • Autoimmune Diseases
  • Non-alcoholic Fatty Liver Disease (NAFLD)
  • Cancer
  • Genetic Disorders
  • Others
• Global Chronic Liver Diseases Therapeutics Market, By Distribution type:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Chronic Liver Diseases Therapeutics, By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Astellas Pharma Inc 
  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline Plc
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi S.A
  • Pfizer Inc.
  • Takeda Pharmaceutical
  • Valeant Pharmaceuticals
  • Watson Pharmaceuticals, Inc.
  • Theratechnologies Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Protagonist Therapeutics, Inc.
  • Dicerna Pharmaceuticals, Inc.
  • Endo International
  • Provectus Biopharmaceuticals Inc.
  • MAX BioPharma, Inc.